Loading
A phase 1/2 trial of RPTR-1-201 in advanced solid tumours, run by Repertoire Immune Medicines, now recruiting.
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07293754 by Repertoire Immune Medicines, with 150 participants planned, started 2025-12-12 and due to reach its primary completion in 2028-12-15. Interventions recorded: RPTR-1-201 and PD-1 / PD-L1 monoclonal antibody.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-L1, PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/